An Effective Strategy Against Tamoxifen Resistance Discovered

Estrogen receptor -positive (ER +) breast cancer cells depend on the presence of estrogen to grow and proliferate. Drugs that prevent estrogen production or its action in cells are therefore called hormonal therapies and form one of the main treatments for hormone-positive breast cancers. Tamoxifenwas one of the first drugs discovered for this purpose and is among the most commonly preferred. However, most tumors in advanced breast cancer eventually develop tamoxifen resistance. Understanding these resistance mechanisms is very important for developing effective treatments. In April 2019, a study published in Nature discovered a strategy to overcome tamoxifen resistance in patients with estrogen receptor-positive breast cancer.
As we know, amino acids are the basic building blocks of proteins. There are 20 types of amino acids in our bodies. Of these, 9 cannot be synthesized by the body and must be obtained from food; these are called essential amino acids. This study investigated the effect of levels of the amino acid leucine on estrogen receptor-positive breast cancer growth in cell cultures.
According to the Study Results;
- Low levels of the amino acid leucine were discovered to suppress ER+ breast cancer cell growth.
- Tamoxifen-resistant breast cancer cells, however, continued to proliferate despite low leucine levels. A protein called SLC7A5 on the cancer cell surface was found to transport leucine into the cells. SLC7A5 protein activity was very high in tamoxifen-resistant breast cancer cells.
- Increased SLC7A5 activity was observed to allow more leucine into cells and make breast cancer cells resistant to tamoxifen.
- In mouse models, suppressing SLC7A5 protein activity with an inhibitor was shown to shrink ER+ tumors.
So What Does This Study Mean for Us?
- The amino acid leucine was discovered to confer tamoxifen resistance in ER+ breast cancer cells.
- Animal proteins contain more leucine than plants. Dietary planning strategies could be developed for patients with OR+ breast cancer with this consideration in mind.
- Lowering leucine levels may benefit patients diagnosed with ER+ breast cancer. However, this claim needs to be proven through further analyses.
- Clinical studies need to be planned to investigate the clinical benefits of low-leucine diets in ER+ breast cancer patients. It should be emphasized that the studies are still at the laboratory stage.
Sources
LLGL2 rescues nutrient stress by promoting leucine uptake in ER+ breast cancer.
Nature, 17 April 2019
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.